Compass Therapeutics (CMPX) Leases (2023 - 2025)
Compass Therapeutics' Leases history spans 3 years, with the latest figure at $9.1 million for Q4 2025.
- For Q4 2025, Leases rose 35.18% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.1 million, up 35.18%, while the annual FY2025 figure was $9.1 million, 35.18% up from the prior year.
- Leases for Q4 2025 was $9.1 million at Compass Therapeutics, down from $9.5 million in the prior quarter.
- Across five years, Leases topped out at $9.8 million in Q2 2025 and bottomed at $1.2 million in Q2 2024.
- The 3-year median for Leases is $4.6 million (2023), against an average of $5.0 million.
- The largest annual shift saw Leases tumbled 51.66% in 2024 before it skyrocketed 750.3% in 2025.
- A 3-year view of Leases shows it stood at $1.8 million in 2023, then surged by 279.0% to $6.7 million in 2024, then soared by 35.18% to $9.1 million in 2025.
- Per Business Quant, the three most recent readings for CMPX's Leases are $9.1 million (Q4 2025), $9.5 million (Q3 2025), and $9.8 million (Q2 2025).